Transplant Registrants With Implanted Left Ventricular Assist Devices Have Insufficient Risk to Justify Elective Organ Procurement and Transplantation Network Status 1A Time

被引:52
作者
Dardas, Todd [1 ]
Mokadam, Nahush A. [2 ]
Pagani, Francis [3 ]
Aaronson, Keith [4 ]
Levy, Wayne C. [1 ]
机构
[1] Univ Washington, Div Cardiol, Seattle, WA 98195 USA
[2] Univ Washington, Div Cardiac Surg, Seattle, WA 98195 USA
[3] Univ Michigan, Sect Cardiac Surg, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Div Cardiovasc Dis, Ann Arbor, MI 48109 USA
关键词
heart failure; left ventricular assist device; transplant; ADVANCED HEART-FAILURE; CIRCULATORY SUPPORT;
D O I
10.1016/j.jacc.2012.02.031
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives The goal of this research was to identify disparities in risk within heart transplant urgency designations. Background Patients with left ventricular assist devices (LVADs) are given 30 days of elective status 1A time. This allowance may create competition for organs between stable LVAD-supported registrants and less stable registrants listed status 1A or 1B. Methods The Scientific Registry of Transplant Recipients database was analyzed for all status 1A and 1B listings between 2005 and 2010. Cox models were used to estimate the relative and absolute risk of adverse events (death or delisting as too ill) during status 1A or 1B listing. Results Status 1A registrants supported with dual inotropes and right heart monitoring had a higher risk of adverse events compared to those supported with implanted LVADs using elective 1A time (hazard ratio: 3.2; 95% confidence interval: 1.8 to 5.7). The 30-day risk of events was 1% (95% confidence interval: 0.1% to 3%) for implanted LVADs using elective 1A time and 6% (95% confidence interval: 4% to 8%) for dual inotrope support. Registrants listed with paracorporeal ventricular assist devices had a higher risk of adverse events (hazard ratio: 9.1; p < 0.0001) compared with registrants with implanted LVADs using elective 1A time. The odds of transplant were higher for implanted LVADs (odds ratio: 1.5; p < 0.0001) compared with dual-inotrope and intra-aortic balloon pump support. Conclusions The historic allowance for 30 days of elective status 1A time for implanted LVADs creates disparities in risk among status 1A registrants. The allowance of 30 days of elective status 1A time should not be allocated to stable registrants with implanted LVADs. Registrants supported with paracorporeal ventricular assist devices should be listed status 1A indefinitely. (J Am Coll Cardiol 2012;60:36-43) (C) 2012 by the American College of Cardiology Foundation
引用
收藏
页码:36 / 43
页数:8
相关论文
共 8 条
  • [1] Use of a continuous-flow device in patients awaiting heart transplantation
    Miller, Leslie W.
    Pagani, Francis D.
    Russell, Stuart D.
    John, Ranjit
    Boyle, Andrew J.
    Aaronson, Keith D.
    Conte, John V.
    Naka, Yoshifumi
    Mancini, Donna
    Delgado, Reynolds M.
    MacGillivray, Thomas E.
    Farrar, David J.
    Frazier, O. H.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (09) : 885 - 896
  • [2] Stable patients on left ventricular assist device support have a disproportionate advantage: Time to re-evaluate the current UNOS policy
    Moazami, Nader
    Sun, Benjamin
    Feldman, David
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2011, 30 (09) : 971 - 974
  • [3] Extended Mechanical Circulatory Support With a Continuous-Flow Rotary Left Ventricular Assist Device
    Pagani, Francis D.
    Miller, Leslie W.
    Russell, Stuart D.
    Aaronson, Keith D.
    John, Ranjit
    Boyle, Andrew J.
    Conte, John V.
    Bogaev, Roberta C.
    MacGillivray, Thomas E.
    Naka, Yoshifumi
    Mancini, Donna
    Massey, H. Todd
    Chen, Leway
    Klodell, Charles T.
    Aranda, Juan M.
    Moazami, Nader
    Ewald, Gregory A.
    Farrar, David J.
    Frazier, O. Howard
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (04) : 312 - 321
  • [4] Long-term use of a left ventricular assist device for end-stage heart failure
    Rose, EA
    Gelijns, AC
    Moskowitz, AJ
    Heitjan, DF
    Stevenson, LW
    Dembitsky, W
    Long, JW
    Ascheim, DD
    Tierney, AR
    Levitan, RG
    Watson, JT
    Meier, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (20) : 1435 - 1443
  • [5] Advanced Heart Failure Treated with Continuous-Flow Left Ventricular Assist Device
    Slaughter, Mark S.
    Rogers, Joseph G.
    Milano, Carmelo A.
    Russell, Stuart D.
    Conte, John V.
    Feldman, David
    Sun, Benjamin
    Tatooles, Antone J.
    Delgado, Reynolds M., III
    Long, James W.
    Wozniak, Thomas C.
    Ghumman, Waqas
    Farrar, David J.
    Frazier, O. Howard
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (23) : 2241 - 2251
  • [6] Results of the Post-US Food and Drug Administration-Approval Study With a Continuous Flow Left Ventricular Assist Device as a Bridge to Heart Transplantation A Prospective Study Using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support)
    Starling, Randall C.
    Naka, Yoshifumi
    Boyle, Andrew J.
    Gonzalez-Stawinski, Gonzalo
    John, Ranjit
    Jorde, Ulrich
    Russell, Stuart D.
    Conte, John V.
    Aaronson, Keith D.
    McGee, Edwin C., Jr.
    Cotts, William G.
    DeNofrio, David
    Duc Thinh Pham
    Farrar, David J.
    Pagani, Francis D.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (19) : 1890 - 1898
  • [7] STEVENSON LW, 1992, CIRCULATION, V86, P224
  • [8] INTERMACS Profiles of Advanced Heart Failure: The Current Picture
    Stevenson, Lynne Warner
    Pagani, Francis D.
    Young, James B.
    Jessup, Mariell
    Miller, Leslie
    Kormos, Robert L.
    Naftel, David C.
    Ulisney, Karen
    Desvigne-Nickens, Patrice
    Kirklin, James K.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2009, 28 (06) : 535 - 541